Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPIEC is an enteric-coated micropellet capsule formulation of aspirin (acetylsalicylic acid) developed by Jilin Tianheng Pharmaceutical. It is designed to provide controlled release of aspirin in the small intestine, thereby reducing gastric mucosal irritation commonly associated with standard aspirin tablets. The micropellet technology aims to improve the bioavailability and safety profile of aspirin for the treatment and prevention of cardiovascular diseases, such as unstable angina pectoris. By utilizing enteric-coated micropellets within a capsule, the formulation ensures a more uniform distribution in the gastrointestinal tract and potentially more stable plasma concentrations. Aspirin acts as an irreversible inhibitor of cyclooxygenase enzymes, primarily COX-1 in platelets, which prevents the synthesis of thromboxane A2 and results in a potent antithrombotic effect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SPIEC.